Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma
المؤلفون المشاركون
Zhou, Yinghong
Dong, Xiaofeng
Xiu, Peng
Wang, Xin
Yang, Jianrong
Li, Lei
Li, Zhongchao
Sun, Pengfei
Shi, Xuetao
Zhong, Jingtao
المصدر
Oxidative Medicine and Cellular Longevity
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-15، 15ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-03-24
دولة النشر
مصر
عدد الصفحات
15
التخصصات الرئيسية
الملخص EN
Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression is associated with hypoxia and the induction of hypoxia-inducible factor (HIF).
Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies.
However, the underlying mechanism remains to be elucidated in HCC, especially under hypoxic conditions.
The alteration of COX-2 and HIF-1α oncogenicity was evaluated in HCC specimens by tissue microarray.
Cell viability, angiogenesis assays, and xenografted nude mice were used to evaluate the effects of meloxicam, along with flow cytometry to detect the cell cycle, apoptosis, and mitochondrial membrane potential (ΔΨm) of HCC.
qRT-PCR, Western blotting, immunofluorescence, immunohistochemistry, luciferase assay, and RNAi were carried out to determine the HIF-1α signaling affected by meloxicam.
In this study, we showed that meloxicam exerts antiproliferative and antiangiogenesis efficacy in vitro and in vivo and causes disruption of mitochondrial membrane potential (ΔΨm), thus leading to caspase-dependent apoptosis under hypoxic environments.
Exposure to meloxicam significantly reduced HIF-1α transcriptional activation and expression through sequestering it in the cytoplasm and accelerating degradation via increasing the von Hippel-Lindau tumor suppressor protein (pVHL) in HCC.
These data demonstrated that inhibition of HIF-1α by meloxicam could suppress angiogenesis and enhance apoptosis of HCC cells.
This discovery highlights that COX-2 specific inhibitors may be a promising therapy in the treatment of HCC.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zhou, Yinghong& Dong, Xiaofeng& Xiu, Peng& Wang, Xin& Yang, Jianrong& Li, Lei…[et al.]. 2020. Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity،Vol. 2020, no. 2020, pp.1-15.
https://search.emarefa.net/detail/BIM-1205277
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zhou, Yinghong…[et al.]. Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity No. 2020 (2020), pp.1-15.
https://search.emarefa.net/detail/BIM-1205277
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zhou, Yinghong& Dong, Xiaofeng& Xiu, Peng& Wang, Xin& Yang, Jianrong& Li, Lei…[et al.]. Meloxicam, a Selective COX-2 Inhibitor, Mediates Hypoxia-Inducible Factor- (HIF-) 1α Signaling in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity. 2020. Vol. 2020, no. 2020, pp.1-15.
https://search.emarefa.net/detail/BIM-1205277
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1205277
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر